Alliance Global raised the firm’s price target on Sellas Life Sciences (SLS) to $10 from $7.50 and keeps a Buy rating on the shares after the company presented updates on its two clinical-stage assets, SLS009 and Galinpepimut-S, which are both indicated for patients at different stages of disease in acute myeloid leukemia.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLS:
- Sellas Life Sciences options imply 6.2% move in share price post-earnings
- Sellas Life Sciences to present preclinical SLS009 data at AACR conference
- SELLAS (SLS): Advancing AML Pipeline, Strengthened Balance Sheet, and Upcoming Catalysts Drive Higher Target and Buy Rating
- Sellas announces enrollment of first patient in Phase 2 SLS009 trial
- SELLAS Strengthens Capital Base Through Warrant Exercises